A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Conditions

Idiopathic Pulmonary Fibrosis

What is the purpose of this trial?

The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis.


Participation Guidelines

Age:
45 Years - 85 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Gilead Sciences
Dates:
05/16/2013
Last Updated:
Study HIC#:
1304011925